The past decade has witnessed fluorescently tagged drug molecules gaining significant
attraction in their use as pharmacological tools with which to visualize and interrogate …

Breast cancer has become a common tumor worldwide which seriously endangers people's
health. Early diagnosis and treatment are particularly urgent in order to reduce the onset …

3-Methoxy-17α-ethynylestradiol or mestranol is a prodrug for ethynylestradiol and the
estrogen component of some oral contraceptive formulations. We demonstrate here that a …

Near-infrared (NIR) fluorescent contrast agents are emerging in optical imaging as sensitive,
cost-effective, and nonharmful alternatives to current agents that emit harmful ionizing …

As a result of change in due date, this Review covers the one and two-third-year period
since our last review1 from January 2010 through August 2011. Manuscripts outside this …

Receptor-targeted optical imaging of cancer is emerging as an attractive strategy for early
cancer diagnosis and surgical guidance. The success of such strategy depends largely …

The development of fluorescent ligands for the estrogen receptor (ER) continues to be of
interest. Over the past 20 years, most efforts have focused on appending an expanding …

Hormone-targeted contrast agents bind with functional groups associated with the
physiology of breast cancer leading to improved prognosis. We have synthesized a novel …

Breast cancer is the foremost cause of death among women worldwide. The estrogen
receptors (ERs), a nuclear receptor superfamily member, are closely associated with breast …

Mammographic screening has been validated as an effective way to decrease breast cancer
deaths, responsible for a 30–40% mortality reduction in participating populations. However …